Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Compass PathwaysEli Lilly
Last price
$11.96$1,304.33
Currency
USD
USD
$1.6B$1.1T
-42.66
-$3.61$29.79
2.530.45
0$6.69
00.54%
Sector
HealthHealth
Employees
15650,000
Ticker
$CMPS$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $CMPS or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.